MannKind CorpMNKD
MNKD
About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Employees: 407
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
472% more call options, than puts
Call options by funds: $9M | Put options by funds: $1.57M
58% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 26
13% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 71
5% more funds holding
Funds holding: 240 [Q4 2024] → 252 (+12) [Q1 2025]
2.8% less ownership
Funds ownership: 60.84% [Q4 2024] → 58.04% (-2.8%) [Q1 2025]
18% less capital invested
Capital invested by funds: $1.08B [Q4 2024] → $886M (-$193M) [Q1 2025]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for MNKD.
Financial journalist opinion
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks That May Rocket Higher This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
1 month ago
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Session
Neutral
GlobeNewsWire
1 month ago
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit.
Neutral
Seeking Alpha
1 month ago
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition
MannKind's stock decline is likely due to concerns over Tyvaso DPI competition from Liquidia, but I believe these fears are exaggerated. Tyvaso DPI provides MannKind with a stable revenue base, supporting its focused pipeline and future growth opportunities. MannKind's Technosphere technology holds promise for additional partnerships beyond United Therapeutics, enhancing long-term potential.
Neutral
GlobeNewsWire
1 month ago
MannKind to Present at Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City:
Neutral
Seeking Alpha
2 months ago
MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Michael Castagna – Chief Executive Officer Chris Prentiss – Chief Financial Officer Conference Call Participants Olivia Brayer – Cantor Anish Nikhanj – RBC Andreas Argyrides – Oppenheimer & Co. Yun Zhong – Wedbush Anthony Petrone – Mizuho Operator Good morning, and welcome to the MannKind Corporation First Quarter 2025 Financial Results Earnings Call. As a reminder, this call is being recorded on May 08, 2025, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
Positive
Zacks Investment Research
2 months ago
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 2024 1Q 2025 net income of $13M, + 24% v.
Neutral
GlobeNewsWire
2 months ago
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Neutral
GlobeNewsWire
3 months ago
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
Daly to showcase striking “Tired of Pricks?” livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13 Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLAKE VILLAGE, Calif.
Charts implemented using Lightweight Charts™